NCT02796651 - Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb) | Biotech Hunter

Enrollment

132

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

December 7, 2016

Study Completion Date

December 7, 2016

Conditions

Chronic Obstructive Pulmonary Disease - COPD

Interventions

DRUG

Formoterol fumarate (6 μg)

Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)

DRUG

Formoterol furmarate (20 μg)

Oral Inhalation (via a standard jet nebulizer connected to an air compressor.

DRUG

Placebo for formoterol fumarate

Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)

DRUG

Formoterol fumarate (12 μg)

Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)

DRUG

Formoterol fumarate (40 μg)

Oral Inhalation (via a standard jet nebulizer connected to an air compressor.

Trial Locations (20)

28054

Research Site, Gastonia

28207

Research Site, Charlotte

29303

Research Site, Spartanburg

29372

Research Site, Rock Hill

29615

Research Site, Greenville

29640

Research Site, Easley

30046

Research Site, Lawrenceville

32720

Research Site, DeLand

32825

Research Site, Orlando

33756

Research Site, Clearwater

34747

Research Site, Celebration

63141

Research Site, St Louis

76543

Research Site, Killeen

78006

Research Site, Boerne

85006

Research Site, Phoenix

85283

Research Site, Tempe

85306

Research Site, Glendale

89102

Research Site, Las Vegas

97202

Research Site, Portland

97504

Research Site, Medford